GlassScriptPhysician profile
Russell Carter
NPI 1912976085
$5,262.14
in general payments reported to CMS, 2019-2025
26 companies · $2,589 in 2025
The $2,589 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $56.69 · 2021: $45.94 · 2022: $228 · 2023: $456 · 2024: $1,765 · 2025: $2,589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,797 · Education: $13.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,796.93 |
| Education | $13.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,285.29 | 2021-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $908.25 | 2022-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $678.88 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Phathom Pharmaceuticals, INC. | $548.54 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $253.07 | 2020-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $223.19 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $190.47 | 2019-2025 | |
| Gilead Sciences, INC. | $149.88 | 2019-2024 | |
| Ardelyx, INC. | $149.19 | 2024-2025 | Ibsrela |
| Qol Medical, LLC | $114.38 | 2024-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $101.83 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $99.37 | 2023-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $87.03 | 2025 | Tremfya |
| Braintree Laboratories, INC. | $80.37 | 2022-2025 | Sutab, Suflave |
| Lilly USA, LLC | $60.80 | 2025 | Omvoh |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $53.37 | 2024-2025 | Vegzelma, Zymfentra |
| Ferring Pharmaceuticals INC. | $47.53 | 2023-2024 | Rebyota |
| Albireo Pharma, INC. | $44.80 | 2024 | Iqirvo, Bylvay |
| Ironwood Pharmaceuticals, INC | $43.81 | 2023-2024 | Linzess |
| Merck Sharp & Dohme LLC | $35.47 | 2019 | |
| Daiichi Sankyo INC. | $23.88 | 2024 | Injectafer |
| Evoke Pharma, INC. | $22.76 | 2024 | |
| Novo Nordisk INC | $18.79 | 2025 | Wegovy |
| Endogastric Solutions, INC | $16.34 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.33 | 2024 | Cyltezo |
| Olympus America INC. | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.